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A B S T R A C T
The newly launched Afﬁnity Binder Knockdown Initiative encourages antibody suppliers and users to
join this public–private partnership, which uses crowdsourcing to collect characterization data on
antibodies. Researchers are asked to share validation data from experiments where gene-editing
techniques (such as siRNA or CRISPR) have been used to verify antibody binding. The initiative is launched
under the aegis of Antibodypedia, a database designed to allow comparisons and scoring of publicly
available antibodies towards human protein targets. What is known about an antibody is the foundation
of the scoring and ranking system in Antibodypedia.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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journal home page: www.elsevier .com/ locat e/euprotThere is a large amount of publicly available afﬁnity binders and
many of them have been shown to not yield reliable results in
speciﬁc applications as outlined in many articles during the last
years [1–4]. Several studies suggest that a large fraction of the
commercially available antibodies are not functional in certain
applications [5,6]. Recently, this has been identiﬁed as a major
problem in life science research, and a number of suggestions have
been put forward on how to improve the quality and reproduc-
ibility of research results using antibodies [7–10]. Clearly, a quality
assurance program in life science research that improves the
validation of antibodies for speciﬁc applications will help to save
material, time, and ﬁnancial resources for the user community.
Many researchers rely on published data and examine primary
data, such as validation images, to make educated choices when
selecting an antibody. Considering the amount of money spent on
research antibodies, estimated to be $2 billion in 2014 [11], the
amount of antibody related knowledge among researchers should
be enormous. Many antibody providers are aware of the gold mine
of knowledge residing in the research community, and currently a
number of initiatives have been launched to collect data from
antibody users, such as the Novus Rewards Program and the LSBio
Rewards Program. These programs are tied to the manufacturers’* Corresponding author.
E-mail address: tove.alm@scilifelab.se (T. Alm).
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creativecommons.org/licenses/by/4.0/).antibody portfolio, and therefore an initiative allowing a more
general and broad collection of data would be of interest.
Antibodypedia (www.antibodypedia.org) is an open source
database for searching and comparing validated antibodies
available to the public through various providers. What is known
about an antibody is the basis for the scoring and ranking system in
Antibodypedia. Validation recommendation weights are applied
for each application, and reference citation weights are applied to
the antibody as a whole, to produce a score indicating an antibody’s
overall performance (see Table 1). The validation and reference
scores are added to a ﬁnal overall score for the antibody. The score
then determine the order in which both provider and antibody are
listed for any gene.
The recently developed gene-editing techniques, using siRNA
and CRISPR, offer possibilities to characterize antibodies in ways
previously not possible. By using gene silencing, the expression of a
target protein can be reduced or eliminated, and the antibody’s
binding to a speciﬁc target can thus be veriﬁed using a genetic-
based method. The reduced or eliminated protein expression is
conﬁrmed and visualized using any antibody based application,
such as immunocytochemistry or western blot. Once the target
binding of the antibody has been conﬁrmed, the target-validation
of the antibody will not need to be reconﬁrmed using additional
methods for visualization. The importance of conﬁrming the
antibody’s binding to the intended target is emphasized by the size
of the score given to this type of validation (see Table 1). The
situation is slightly different for application speciﬁc validation ofics Association (EuPA). This is an open access article under the CC BY license (http://
Table 1
Validation data and citations weights.
Primary data Score References Score
Supportive knockdown/knockout data in Antibodypedia (image and details present) 6 >50 citations (per antibody) 6
Supportive data in Antibodypedia (image and details present, per application) 1 21–50 citations (per antibody) 5
Supportive data on provider website (per application) 0.75 11–20 citations (per antibody) 4
Data presented in Antibodypedia (inconclusive; per application) 0.5 4–10 citations (per antibody) 3
Recommended by provider, but no data available (per application) 0.25 2–3 citations (per antibody) 2
1 citation (per antibody) 1
[No information] 0 [No references] 0
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bind the target protein in a certain experimental setup. Function-
ality of the antibody is dependent on the context and application
used, and hence validation of the antibody performance in each
application is needed. Therefore, the score from the individual
application speciﬁc validations are additive. Currently, Antibody-
pedia supports the following 15 applications: chromatin immu-
noprecipitation, functional assay, gel shift, immunoelectron
microscopy, proximity ligation assay, radioimmunoassay, reverse
phase protein array, blocking/neutralizing, ELISA, ﬂow cytometry,
immunocytochemistry, immunohistochemistry, immunoprecipi-
tation, protein array, and western blot.
The Afﬁnity Binder Knockdown Initiative (www.antibodypedia.
com/text/knockdown_initiative) has been launched under the
aegis of Antibodypedia with the aim to promote validation of
antibodies using the genetic methods outlined above (siRNA and
CRISPR). The initiative uses crowdsourcing to gather information
from knockdown or knockout experiments performed by the
research community in order to validate speciﬁc antibodies.
Antibodypedia supports the initiative by offering a standardized
system for sharing validation data and references about publicly
available antibodies with the purpose of providing the research
community with information on the effectiveness of speciﬁc
antibodies in speciﬁc applications. By encouraging the research
community and life science companies to collaborate, the initiative
hopes to improve the knowledge about speciﬁc afﬁnity reagents.
Academic institutions and commercial companies are invited to
upload information on antibody and antigen, and users of the
database may submit their data to complement the existing
knowledge about an antibody.
Scientists, that use knockdown or knockout validation in their
research, are encouraged to upload their knockdown or knockoutFig. 1. Heterogeneous nuclear ribonucleoprotein U-like 1 (HNRNPUL1) is a nuclear RNA
Confocal images of immunoﬂuorescently stained human U-2 OS cells; the protein HNRNP
transfected with control siRNA, and the image to the right shows cells where HNRNPUL1 h
online on www.antibodypedia.com/gene/17170/HNRNPUL1/antibody/693797/HPA0462validation results to the publicly available database Antibodypedia.
The submission process is a simple web format, and asks for
information on the reagents used, experimental data (image and
details on results), and a protocol (pdf); the submission process
should only take a couple of minutes. Participating industrial
partners include their antibodies and/or gene silencing reagents
(siRNA/CRISPR) in the initiative, and will reward the ﬁrst positive
knockdown validation for each included reagent (antibody, siRNA,
CRISPR) that is submitted to Antibodypedia on www.antibodype-
dia.com/validate.php. To qualify for a reward, the knockdown on
protein level must be at least 50%. An example is visualized in the
knockdown validation performed in Fig. 1. In this example, the
staining intensity in the ﬂuorescent images has been quantiﬁed
using image analysis. Approximately 200 cells per siRNA and
control, respectively, were segmented and the intensity measured.
In this way an exact measure of the downregulation can be
obtained as described in Stadler et al. [4]. This method conﬁrms the
antibody’s binding to its intended target. However, in cases where
the expression is only partly silenced it is difﬁcult to address the
level of cross-reactivity.
Several antibody companies and reagent suppliers have
expressed great interest in the initiative, and currently Atlas
Antibodies, Aviva Systems Biology, Novus Biologicals, R&D
Systems, and Invitrogen Antibodies from Thermo Fisher Scientiﬁc
have included their antibodies in the Afﬁnity Binder Knockdown
Initiative. In addition, siRNA reagents from Thermo Fisher
Scientiﬁc are also included in the reward program.
Identifying good afﬁnity reagents is key to improved reproduc-
ibility and advancement of science. Most research is in one way or
another relying on other scientiﬁc ﬁndings. Apart from character-
izing an antibody and conﬁrming its target binding, reproducibility
is also dependent on the ability to identify the reagent used. Proper-binding protein that binds speciﬁcally to the adenovirus E1B–55 kDa oncoprotein.
UL1 is shown in green and the microtubules in red. The image to the left shows cells
as been downregulated more than 75% with speciﬁc siRNA. This data can be viewed
90.
58 T. Alm et al. / EuPA Open Proteomics 10 (2016) 56–58citation of antibodies in publications is important and minimum
requirement is antibody provider name and catalog number.
However, in a study by Vasilevsky et al., less than 50% of the
antibodies were identiﬁable [12]. This issue has been addressed by
the Resource Identiﬁcation Initiative, which gives unique identi-
ﬁers to antibodies. The Research Resource Identiﬁers (RRIDs) are
free to generate, consistent across journals and papers, and
machine readable [13]. The ability to easily ﬁnd out in which
experiments an antibody has been used in is very useful for a
scientist, and the Afﬁnity Binder Knockdown Initiative will work
on providing knockdown and knockout validated antibodies with a
unique identiﬁer.
With the Afﬁnity Binder Knockdown Initiative we hope to raise
the awareness of the issues concerning the validations of
antibodies and to highlight the new possibilities with the recently
introduced gene-editing techniques. Ideally, providers should
validate all antibodies in their portfolio using gene editing, an
antibody-independent method, or with independent antibodies to
conﬁrm antibody target. This is, however, a continuous work that
will not happen overnight, and in the meantime we should explore
any given possibility to improve the antibody market. Many
researchers have existing knowledge on individual antibodies that
would be of great value to other researchers. We ask you to
contribute with your knowledge on the antibodies that you use, to
help make the antibody market a better place.
The Afﬁnity Binder Knockdown Initiative started on September
28, 2015, and ends on September 30, 2016. During this period, the
Afﬁnity Binder Knockdown Initiative will be open for rewards in
Europe and North America. A report of the initiative will be given at
the HUPO World Conference 2016 in Taipei. If antibody providers
are interested in continuing their participation, the initiative will
continue in its current setup. The possibility to upload knockdown
data will continue to be available on Antibodypedia despite the
involvement from companies; however, the reward system is only
applicable as long as companies are participating. Hopefully this
initiative will serve as a starting point to unite the research
community to shared efforts. One could for example envision
repositories with knockdown cell lysates to allow reproducible
assay testing.
Initiative organizers are Prof. Mathias Uhlén, Asst. Prof. Emma
Lundberg, and Dr. Tove Alm. For speciﬁc details and submission go
to: www.antibodypedia.com/text/knockdown_initiative.
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